Serafin Morales Murillo
Grau: Doctor/a
973 70 53 03
smorales.lleida.ics(ELIMINAR)@gencat.cat
ResearcherID: http://www.researcherid.com/rid/L-7216-2019
Publicacions
-
MORALES MURILLO, SERAFIN; GASOL CUDOS, ARIADNA; VELASCO SANCHEZ, ANA; MARTINEZ ORTIN, DAVID; SALLA FORTUNY, JOEL; TEJERO NARBONA, RUBEN; SERRATE LOPEZ, ANNA ALBA; VILARDELL VILLELLAS, FELIPE; SALUD SALVIA, ANTONIA
Clinical and Biological Factors Associated with ISH Amplification in HER2 2+ by IHC in Breast Cancer Patients
Biomedical Journal of Scientific & Technical Research -. .
-
Gavila, J; Oliveira, M; Pascual, T; Perez-Garcia, J; Gonzàlez X; Canes, J; Pare, L; Calvo, I; Ciruelos, E; Muñoz M; Virizuela, JA; Ruiz, I; Andres, R; Perello, A; Martinez, J; Morales, S; Marin-Aguilera, M; Martinez, D; Quero, JC; Llombart-Cussac, A; Prat, A
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
BMC MEDICINE 17 8-8. .
-
Sanchez-Rovira, P; Zamora, P; Salvador-Bofill, J; Morales, S; Martinez-Janez, N; Martinez-de-Duenas, E; Lluch, A; Illarramendi, JJ; Gomez-Pardo, P; Gavilá Gregori J; Garcia-Palomo, A; Garcia-Mata, J; Fernandez, Y; del Barco, S; de Juan, A; Ciruelos, E; Chacon, JI; Calvo, L; Barnadas, A; Albanell, J
Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists
Journal Of Drug Assessment 8 62-69. .
-
von Minckwitz, G; Colleoni, M; Kolberg, HC; Morales, S; Santi, P; Tomasevic, Z; Zhang, N; Hanes, V
Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial
LANCET ONCOLOGY 19 987-998. .
-
Gennari A; Sun Z; Hasler-Strub U; Colleoni M; Kennedy MJ; Von Moos R; Cortés J; Vidal MJ; Hennessy B; Walshe J; Parraga KA; Ribi K; Bernhard J; MORALES, S.; Pagani O; Barbeaux A; Borstnar S; Rabaglio-Poretti M; Maibach R; Regan MM; Jerusalem G; International Breast Cancer Study Group, Cancer Trials Ireland and SOLTI Group
A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial
ANNALS OF ONCOLOGY 29 661-668. .
-
Gianni, L; Mansutti, M; Anton, A; Calvo, L; Bisagni, G; Bermejo, B; Semiglazov, V; Thill, M; Chacon, JI; Chan, A; Morales, S; Alvarez, I; Plazaola, A; Zambetti, M; Redfern, AD; Dittrich, C; Dent, RA; Magazzu, D; De Fato, R; Valagussa, P; Tusquets, I
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial A Randomized Phase 3 Clinical Trial
JAMA Oncology 4 302-308. .
-
Rugo, HS; Tredan, O; Ro, J; Morales, SM; Campone, M; Musolino, A; Afonso, N; Ferreira, M; Park, KH; Cortes, J; Tan, AR; Blum, JL; Eaton, L; Gause, CK; Wang, Z; Im, E; Mauro, DJ; Jones, MB; Denker, A; Baselga, J
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer
BREAST CANCER RESEARCH AND TREATMENT 165 601-609. .
-
Novell, A; Morales, S; Valls J; Panades, MJ; Salud, A; Iglesias, E; Vilardell, F; Matias-Guiu, X; Llombart-Cussac, A
Novel biomarkers in primary breast core biopsies to predict poor response to neoadjuvant chemotherapy and appearance of metastases
HISTOLOGY AND HISTOPATHOLOGY 32 909-915. .
-
von Minckwitz, G.; Ponomarova, O.; Morales, S.; Zhang, N.; Hanes, V.
Efficacy and safety of biosimilar ABP 980 compared with trastuzumab in HER2 positive early breast cancer
ANNALS OF ONCOLOGY 28 -. .
-
Villagrasa Gonzalez, P.; Prat, A.; Oliveira, M.; de la Pena, L.; Gonzalez, X.; Cortes Castan, J.; Rios, J.; Vazquez, J.; Martinez Janez, N.; Perello Martorell, A.; Garau, I.; Martinez de Duenas, E.; Morales, S.; Mele, M.; Bermejo De las Heras, B.; Ciruelos, E.
SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER plus ) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer
ANNALS OF ONCOLOGY 28 -. .
-
Morales, S.; Gasol Cudos, A.; Novell Alvarez, A.; Vilardell Villellas, F.; Panades Siurana, M. J.; Canosa Morales, C.; Mele Olive, J.; Iglesias Martinez, E.
Vitamin D as a prognostic factor in triple negative early breast cancer
ANNALS OF ONCOLOGY 28 -. .
-
von Minckwitz G; Procter M; de Azambuja E; Zardavas D; Benyunes M; Viale G; Suter T; Arahmani A; Rouchet N; Clark E; Knott A; Lang I; Levy C; Yardley DA; Bines J; Gelber RD; Piccart M; Baselga J; APHINITY Steering Committee and Investigators
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
NEW ENGLAND JOURNAL OF MEDICINE 377 122-131. .
Projectes
- Development of Computer Application (Apps) for Information and Monitoring of Patients with Breast Cancer at the Hospital Arnau de Vilanova De Lleida
- SELECCIÓN DE TRATAMIENTO CON QUIMIOTERAPIA NEOADYUVANTE EN PACIENTES CON CÁNCER DE MAMA EN ESTADIO PRECOZ Y CON RECEPTORES HORMONALES POSITIVOS MEDIANTE LA DETERMINACIÓN DE LA PLATAFORMA ONCOTYPE, CF DNA EN SANGRE PERIFÉRICA Y CAMBIOS DEL MARCADOR KI67 EN TEJIDO TUMORAL.
- Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante